NasdaqCM:VERU

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. More Details


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Veru's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VERU is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 32% a week.

Volatility Over Time: VERU's weekly volatility has increased from 18% to 32% over the past year.


Market Performance


7 Day Return

-13.2%

VERU

-1.6%

US Personal Products

-3.4%

US Market


1 Year Return

219.2%

VERU

44.2%

US Personal Products

29.4%

US Market

Return vs Industry: VERU exceeded the US Personal Products industry which returned 44.2% over the past year.

Return vs Market: VERU exceeded the US Market which returned 29.4% over the past year.


Shareholder returns

VERUIndustryMarket
7 Day-13.2%-1.6%-3.4%
30 Day36.4%14.9%0.6%
90 Day300.9%17.5%6.3%
1 Year219.2%219.2%45.1%44.2%32.2%29.4%
3 Year692.2%692.2%62.8%56.4%51.3%41.7%
5 Year432.4%432.4%109.4%93.1%119.6%95.2%

Long-Term Price Volatility Vs. Market

How volatile is Veru's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Veru undervalued compared to its fair value and its price relative to the market?

574.09x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: VERU ($13.15) is trading above our estimate of fair value ($1.72)

Significantly Below Fair Value: VERU is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: VERU is poor value based on its PE Ratio (574.1x) compared to the US Personal Products industry average (19.5x).

PE vs Market: VERU is poor value based on its PE Ratio (574.1x) compared to the US market (21.4x).


Price to Earnings Growth Ratio

PEG Ratio: VERU is poor value based on its PEG Ratio (6.7x)


Price to Book Ratio

PB vs Industry: VERU is overvalued based on its PB Ratio (19.4x) compared to the US Personal Products industry average (2.6x).


Next Steps

Future Growth

How is Veru forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

85.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VERU's forecast earnings growth (85.3% per year) is above the savings rate (2%).

Earnings vs Market: VERU's earnings (85.3% per year) are forecast to grow faster than the US market (19.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VERU's revenue (46.9% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: VERU's revenue (46.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VERU's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Veru performed over the past 5 years?

-30.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VERU has a large one-off gain of $4.3M impacting its December 31 2020 financial results.

Growing Profit Margin: VERU became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: VERU has become profitable over the past 5 years, growing earnings by -30% per year.

Accelerating Growth: VERU has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: VERU has become profitable in the last year, making it difficult to compare its past year earnings growth to the Personal Products industry (17.1%).


Return on Equity

High ROE: VERU's Return on Equity (3.2%) is considered low.


Next Steps

Financial Health

How is Veru's financial position?


Financial Position Analysis

Short Term Liabilities: VERU's short term assets ($47.6M) exceed its short term liabilities ($17.1M).

Long Term Liabilities: VERU's short term assets ($47.6M) exceed its long term liabilities ($7.0M).


Debt to Equity History and Analysis

Debt Level: VERU's debt to equity ratio (29.5%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if VERU's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: VERU's debt is not well covered by operating cash flow (8.6%).

Interest Coverage: VERU's interest payments on its debt are not well covered by EBIT (0.4x coverage).


Balance Sheet


Next Steps

Dividend

What is Veru current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VERU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VERU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VERU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VERU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: VERU is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VERU's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Mitch Steiner (59 yo)

4.42yrs

Tenure

US$1,263,303

Compensation

Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 &...


CEO Compensation Analysis

Compensation vs Market: Mitch's total compensation ($USD1.26M) is below average for companies of similar size in the US market ($USD2.20M).

Compensation vs Earnings: Mitch's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Mitchell Steiner
Chairman4.42yrsUS$1.26m9.41%
$ 97.0m
Harry Fisch
Vice Chairman & Chief Corporate Officer3yrsUS$578.30k10.34%
$ 106.6m
Michele Greco
CFO & Chief Administrative Officer3yrsUS$549.00k0.12%
$ 1.3m
K. Barnette
Chief Scientific Officer2.5yrsUS$623.63k0%
$ 0
Samuel Fisch
Director of Investor Relations1.92yrsno datano data
Philip Greenberg
Executive VP of Legal & Secretary3.08yrsno datano data
Kevin Gilbert
Executive Vice President of Corporate Development4.17yrsno datano data
Robert Getzenberg
Executive Vice President for Medical Affairs1.17yrsUS$485.91kno data
Phillip Kuhn
Executive Vice President of Strategy & Commercialno datano datano data
Domingo Rodriguez
Executive Vice President of Clinical Operations2.92yrsno datano data
Gary Bird
Senior Vice President of Quality Oversight2.08yrsno datano data

3.0yrs

Average Tenure

59yo

Average Age

Experienced Management: VERU's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Mitchell Steiner
Chairman4.42yrsUS$1.26m9.41%
$ 97.0m
Harry Fisch
Vice Chairman & Chief Corporate Officer3yrsUS$578.30k10.34%
$ 106.6m
Andrew Love
Board Observer4.42yrsno datano data
Michael Rankowitz
Independent Director3yrsUS$61.08k0.13%
$ 1.3m
Mario Eisenberger
Independent Director4.42yrsUS$61.08k0%
$ 0
Jesus Socorro
Independent Director4yrsUS$61.08k0.041%
$ 427.3k
Grace Hyun
Independent Director0.58yrno data0.014%
$ 148.5k

3.0yrs

Average Tenure

61yo

Average Age

Experienced Board: VERU's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: VERU insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.2%.


Top Shareholders

Company Information

Veru Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Veru Inc.
  • Ticker: VERU
  • Exchange: NasdaqCM
  • Founded: 1971
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: US$1.030b
  • Shares outstanding: 78.36m
  • Website: https://www.verupharma.com

Number of Employees


Location

  • Veru Inc.
  • 48 NW 25th Street
  • Suite 102
  • Miami
  • Florida
  • 33127
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VERUNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJul 1990
FMWDB (Deutsche Boerse AG)YesCommon StockDEEURJul 1990

Biography

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection a...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/03 23:55
End of Day Share Price2021/03/03 00:00
Earnings2020/12/31
Annual Earnings2020/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.